Bionevix
Preclinical antibody-drug conjugates targeting activated endothelium in IPF and pulmonary hypertension
Highlights
- New on EvolcAdded 2026-11-12
About Bionevix
Bionevix is a UK biotechnology company developing non-cytotoxic antibody-drug conjugates (ADCs) that deliver small-molecule payloads to disease-activated endothelium. Its lead programme, BNVX-04, is designed to deliver an mTOR inhibitor to activated endothelial cells and is in preclinical development for idiopathic pulmonary fibrosis (IPF) and interstitial lung disease-associated pulmonary hypertension (ILD-PH). Two additional programmes address further fibrotic and immune-mediated disease targets.
The company is at preclinical stage and invites investment and partnering discussions for its programmes. Its intended patients are people with IPF and ILD-PH.
Bionevix was founded in 2021 and is headquartered in London. It received FDA orphan-drug designation for IPF in December 2025 and for pulmonary arterial hypertension in November 2026, and filed a Patent Cooperation Treaty application in August 2026. The team includes founder and CEO Dr Benji Schreiber and Director of Preclinical Development Ged Corbett, with advisers including Professor Toby Maher and Dr John Lambert, former CSO at ImmunoGen.
Product: BNVX-04, a preclinical antibody-drug conjugate designed to deliver an mTOR inhibitor to activated endothelium in IPF and ILD-PH.
Jobs at Bionevix
More biotech & pharma companies
Biorbyt
Life science research reagents and custom products for scientists and research organizations worldwideNew on EvolcBiorelate
Literature-mined cause-and-effect data linking drugs, genes and diseases, for drug discovery and bioinformatics teamsRemote-friendlyBiorex Diagnostics
In vitro diagnostic tests and reagents for hospitals, clinics, blood banks and research facilitiesBiosecure Id
Automated forensic DNA workflow systems and genomics services for forensic laboratories and applied genetics marketsYoung companyNew on EvolcBiostatus
Develops and manufactures fluorescent cell-analysis reagents for research laboratories, screening centres and distributors worldwideNew on EvolcBiovara
Developing an oral therapy for lung cancer cough for patients with advanced lung cancerYoung companyNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- Next.jsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Related technologyimplied by Next.js
Hosting
- VercelHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-vercel-id
- Response headerx-vercel-id
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.